135 related articles for article (PubMed ID: 10721091)
21. Production of polyclonal antibodies against 1,1'-ethyliden bis[L-tryptophan] (EBT), a potential contaminant causing eosinophilia-myalgia syndrome (EMS).
Kurihara N; Yanagisawa H; Jin Z; Wada O
Toxicol Lett; 1993 Mar; 66(3):231-6. PubMed ID: 8475503
[TBL] [Abstract][Full Text] [Related]
22. Epidemiology of potential association between L-tryptophan ingestion and eosinophilia-myalgia syndrome.
Daniels SR; Hudson JI; Horwitz RI
J Clin Epidemiol; 1995 Dec; 48(12):1413-27; discussion 1429-40. PubMed ID: 8543957
[TBL] [Abstract][Full Text] [Related]
23. Characterization of contaminants in EMS-associated L-tryptophan samples by high-performance liquid chromatography.
Toyo'oka T; Yamazaki T; Tanimoto T; Sato K; Sato M; Toyoda M; Ishibashi M; Yoshihira K; Uchiyama M
Chem Pharm Bull (Tokyo); 1991 Mar; 39(3):820-2. PubMed ID: 2070471
[TBL] [Abstract][Full Text] [Related]
24. Analytical characterization of peptide contaminants of L-tryptophan.
Barnhart ER; Maggio VL; Alexander LR; Reilly MC; Gelbaum LT; Turner WE; Hine TK; Needham LL
Arch Environ Contam Toxicol; 1996 Jan; 30(1):142-8. PubMed ID: 8579384
[TBL] [Abstract][Full Text] [Related]
25. Animal models of the eosinophilia-myalgia syndrome.
Clauw DJ
J Rheumatol Suppl; 1996 Oct; 46():93-7; discussion 92, 97-8. PubMed ID: 8895185
[TBL] [Abstract][Full Text] [Related]
26. Eosinophilia-myalgia syndrome in Germany: an epidemiologic review.
Carr L; Rüther E; Berg PA; Lehnert H
Mayo Clin Proc; 1994 Jul; 69(7):620-5. PubMed ID: 8015323
[TBL] [Abstract][Full Text] [Related]
27. Epidemiologic studies of the association of L-tryptophan with the eosinophilia-myalgia syndrome: a critique.
Shapiro S
J Rheumatol Suppl; 1996 Oct; 46():44-58; discussion 58-9. PubMed ID: 8895181
[TBL] [Abstract][Full Text] [Related]
28. L-tryptophan: eosinophilia-myalgia syndrome.
D'Arcy PF
Adverse Drug React Toxicol Rev; 1995; 14(1):37-43. PubMed ID: 7612781
[No Abstract] [Full Text] [Related]
29. Search for contaminant in EMS outbreak goes slowly.
Swinbanks D; Anderson C
Nature; 1992 Jul; 358(6382):96. PubMed ID: 1614552
[No Abstract] [Full Text] [Related]
30. Subchronic toxicity of 3-phenylamino alanine, an impurity in L-tryptophan reported to be associated with eosinophilia-myalgia syndrome.
Sato F; Hagiwara Y; Kawase Y
Arch Toxicol; 1995; 69(7):444-9. PubMed ID: 8526739
[TBL] [Abstract][Full Text] [Related]
31. Is there any relationship between eosinophilia myalgia syndrome (EMS) and fibromyalgia syndrome (FMS)? An analysis of clinical and immunological data.
Barth H; Berg PA; Klein R
Adv Exp Med Biol; 1999; 467():487-96. PubMed ID: 10721092
[TBL] [Abstract][Full Text] [Related]
32. Eosinophilia-myalgia syndrome associated with exposure to tryptophan from a single manufacturer.
Slutsker L; Hoesly FC; Miller L; Williams LP; Watson JC; Fleming DW
JAMA; 1990 Jul; 264(2):213-7. PubMed ID: 2355442
[TBL] [Abstract][Full Text] [Related]
33. Gastrointestinal involvement in L-tryptophan (L-Trp) associated eosinophilia-myalgia syndrome (EMS).
De Schryver-Kecskemeti K; Bennert KW; Cooper GS; Yang P
Dig Dis Sci; 1992 May; 37(5):697-701. PubMed ID: 1563309
[TBL] [Abstract][Full Text] [Related]
34. Review of L-tryptophan and eosinophilia-myalgia syndrome.
Roufs JB
J Am Diet Assoc; 1992 Jul; 92(7):844-50. PubMed ID: 1624654
[TBL] [Abstract][Full Text] [Related]
35. Eosinophilia-myalgia syndrome: coming to grips with a new illness.
Kilbourne EM
Epidemiol Rev; 1992; 14():16-36. PubMed ID: 1289111
[TBL] [Abstract][Full Text] [Related]
36. Bias or biology: evaluating the epidemiologic studies of L-tryptophan and the eosinophilia-myalgia syndrome.
Horwitz RI; Daniels SR
J Rheumatol Suppl; 1996 Oct; 46():60-72. PubMed ID: 8895182
[TBL] [Abstract][Full Text] [Related]
37. [Eosinophilia myalgia syndrome (EMS) caused by L-tryptophan product and toxic oil syndrome (TOS) caused by denatured rape-seed oil].
Maitani T; Saitoh H
Shokuhin Eiseigaku Zasshi; 2009 Dec; 50(6):279-91. PubMed ID: 20065617
[No Abstract] [Full Text] [Related]
38. Metabolism and distribution in the rat of peak E substance, a constituent in L-tryptophan product implicated in eosinophilia-myalgia syndrome.
Adachi J; Naito T; Ueno Y; Ogawa Y; Ninomiya I; Tatsuno Y
Arch Toxicol; 1993; 67(4):284-9. PubMed ID: 8517785
[TBL] [Abstract][Full Text] [Related]
39. Use of tryptophanase in the detection of contaminants in EMS related L-tryptophan.
Simat T; Steinhart H
J Pharm Biomed Anal; 1997 Sep; 16(1):167-73. PubMed ID: 9447564
[No Abstract] [Full Text] [Related]
40. [A case of the eosinophilia-myalgia syndrome].
Ishikawa A; Akahosi T; Okada J; Kondo H; Kasiwazaki S
Ryumachi; 1992 Aug; 32(4):327-30; discussion 330-2. PubMed ID: 1411794
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
